Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220677 | 1.00 | CRHR1 (0.35) | CRHR1MEN1MAPTALOX12KMT2A | |
| SCHEMBL7228112 | 0.93 | ALDH1A1 (0.33) | CRHR1ALDH1A1 | |
| SCHEMBL7228114 | 0.93 | ALDH1A1 (0.33) | CRHR1ALDH1A1 | |
| SCHEMBL7222184 | 0.85 | — | — | |
| SCHEMBL7222180 | 0.85 | — | — | |
| SCHEMBL7219632 | 0.80 | TSHR (0.36) | CRHR1MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL7219628 | 0.80 | TSHR (0.36) | CRHR1MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL7227341 | 0.79 | — | — | |
| SCHEMBL7227339 | 0.79 | — | — | |
| SCHEMBL7220577 | 0.75 | CRHR1 (0.32) | CRHR1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1103553-A2 | Substituted heterocyclic derivatives | Pfizer Products Inc. (US) | 2001-05-30 | — | — | EP | claimed |
| US-6525067-B1 | Corticotropin releasing factor antagonists; such as 1-(2-methyl-8-(2,4,6-trimethyl-phenyl)-quinolin-4-yl)-propan-1-one-oxime | PFIZER INC | 2003-02-25 | — | — | US | disclosed |
| EP-1103553-A2 | Substituted heterocyclic derivatives | Pfizer Products Inc. (US) | 2001-05-30 | — | — | EP | disclosed |